Source: Annual Congress 2011 - Translational models of disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Young, R. Bonnert, E. Cadogan, S. Connolly, P. Gardiner, S. Jordan, D. Nicholls, S. Paine, G. Pairaudeau, M. Stocks (Loughborough, United Kingdom). AZD3199: A fast acting β₂-receptor agonist with a long duration of action. Eur Respir J 2011; 38: Suppl. 55, 858

Member's Comments

No comment yet.

Related content which might interest you: AZD3199: A potent and selective β2-adrenergic receptor agonist with rapid onset of action Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 The in vitro biology of Compound X – a novel β2 adrenoceptor agonist with a long duration of action Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Safety and toleration of pf-00610355, a novel inhaled long acting β2 adrenoreceptor agonist Source: Annual Congress 2009 - New bronchodilators Year: 2009 GB001 is a potent, insurmountable DP2 antagonist with long receptor residence time and extended pharmacodynamic effects Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 A potential role for dissociation rate from the M3 muscarinic receptor in the onset of action of NVA237 and tiotropium Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Compound X – an inhaled β2 agonist with equivalent potency and superior duration of action (DOA)/ therapeutic index (TI) to salmeterol in the anaesthetised dog model of bronchoconstriction Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 LAS100977, a novel β2-agonist, has a longer duration of action and a more favourable therapeutic index than salmeterol in anaesthetised dogs Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Comparison of the efficacy and safety of 5 different doses of the novel very long acting β2-agonist carmoterol Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006 LAS100977 is a novel, potent β2-agonist with rapid onset and sustained duration of action in vitro Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance Source: Annual Congress 2007 - New drugs for COPD Year: 2007 PKA/cAMP-independent transactivation of glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006 Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Indacaterol, a novel 24-hour β2-agonist, demonstrates a long duration of action and fast onset in vitro and in vivo in the guinea pig Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005 Effects of long acting β2-agonist, sustained-release theophylline and their combination on exercise parameters in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 287s Year: 2002 Influence of endorphins and opioid receptors antagonist N-acylstearoilethanolamine (NAE) on Th function in COPD after low dose radiation exposure Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006 The effect of inhaled corticosteroids on the hypothalamic-pituitary-adrenal-axis in short term and long term treatment Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Abediterol, a novel long-acting inhaled beta2-agonist, has a fast association rate and long residence time at human beta2 receptors Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist Source: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007